Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition-Reference-Cited by-同舟云学术

Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition

Published:2024-01-30 Issue:1 Volume:13 Page:
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

He Peng¹,Huang Sijing¹,Wang Rui¹,Yang Yunkai¹,Yang Shangye¹,Wang Yue¹,Qi Mengya¹,Li Jiyang¹,Liu Xiaofen²,Zhang Xuyao¹,Feng Meiqing¹

Affiliation:

1. Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, People’s Republic of China

2. Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China

Funder

National Natural Science Foundation of China

Shanghai Sailing Program

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2023.2294854

Reference53 articles.

1. The emerging NDM carbapenemases

2. Recent research and development of NDM-1 inhibitors

3. NDM metallo-beta-lactamases and their bacterial producers in health care settings;Wu W;Clin Microbiol Rev,2019

4. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications;Iredell J;BMJ,2016

5. Acinetobacter baumannii : Emergence of a Successful Pathogen

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and synthesis of unique indole-benzosulfonamide oleanolic acid derivatives as potent antibacterial agents against MRSA;European Journal of Medicinal Chemistry;2024-10

2. Combination of aloe emodin, emodin, and rhein from Aloe with EDTA sensitizes the resistant Acinetobacter baumannii to polymyxins;Frontiers in Cellular and Infection Microbiology;2024-09-13

3. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials;Expert Opinion on Investigational Drugs;2024-03-06